Diagnostic and treatment resources in Latin America
| Diagnostic resource . | No. of patients (N = 204) . | % . | Countries (N = 9) . |
|---|---|---|---|
| Bone marrow biopsy | |||
| Availability according to survey | 9 | ||
| Availability in preliminary data | 201 | 98 | |
| Paroxysmal nocturnal hemoglobinuria clones | |||
| Availability according to survey | 2 | ||
| Availability in preliminary data | 125 | 61 | |
| Cytogenetics | |||
| Availability according to survey | 3 | ||
| Availability in preliminary data | 92 | 45 | |
| Clastogenic effect of diepoxybutane | |||
| Availability according to survey | 3 | ||
| Availability in preliminary data | 68 | 33 | |
| Telomere length test | |||
| Availability according to survey | 1 | ||
| Availability in preliminary data | 52 | 25 | |
| Treatment availability | |||
| ATG/cyclosporine | 8 | ||
| Horse ATG | 2 | ||
| Stem cell transplantation | 8 | ||
| Unrelated stem cell transplantation | 3 | ||
| Eltrombopag for second-line treatment | 3 |
| Diagnostic resource . | No. of patients (N = 204) . | % . | Countries (N = 9) . |
|---|---|---|---|
| Bone marrow biopsy | |||
| Availability according to survey | 9 | ||
| Availability in preliminary data | 201 | 98 | |
| Paroxysmal nocturnal hemoglobinuria clones | |||
| Availability according to survey | 2 | ||
| Availability in preliminary data | 125 | 61 | |
| Cytogenetics | |||
| Availability according to survey | 3 | ||
| Availability in preliminary data | 92 | 45 | |
| Clastogenic effect of diepoxybutane | |||
| Availability according to survey | 3 | ||
| Availability in preliminary data | 68 | 33 | |
| Telomere length test | |||
| Availability according to survey | 1 | ||
| Availability in preliminary data | 52 | 25 | |
| Treatment availability | |||
| ATG/cyclosporine | 8 | ||
| Horse ATG | 2 | ||
| Stem cell transplantation | 8 | ||
| Unrelated stem cell transplantation | 3 | ||
| Eltrombopag for second-line treatment | 3 |
ATG, antithymocyte globulin.